Targets of Acinetobacter baumannii
Inventors
Urwyler, Simon • Haake, Markus • Rudolf, Michael
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10603373-B2
Publication Date
2020-03-31
Expiration Date
Abstract
The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.
Core Innovation
The invention relates to antigenic Acinetobacter baumannii polypeptide targets and antibodies directed to motif regions for use in vaccine, diagnostic, and therapeutic contexts. Antigenic polypeptides include AB023, AB024, AB025, AB030, AB031L1, FimA, CsuAB, and OmpA, and corresponding nucleic acids and polypeptides are defined using SEQ ID NOs, including fragments, analogs, and derivatives having immunostimulatory activity. The description emphasizes conservation and prevalence across clinical strains and links antibody binding to defined motif sequences.
The invention includes antibody approaches comprising polyclonal and monoclonal antibodies, with embodiments described as effector-function-capable and with preferences toward human antibodies. Specific monoclonal antibody embodiments bind motifs identified in the antigenic polypeptides, including PVDFTVAI (SEQ ID NO:36), and an antibody example is described for the motif FEDFN (SEQ ID NO:37). The disclosure frames these motif-binding antibodies as protective and capable of inducing effector function toward Acinetobacter baumannii.
The description provides immunogenicity and functional evidence for the motif-directed immune response, including binding and immunoassay measurements using convalescent sera and immunized samples. Experimental readouts reported include ELISA/ELISA titres, immunoblots, binding/inhibition/agglutination/FACS, bactericidal activity, and effects on survival in active and passive mouse pneumonia models. Epitope mapping is described using peptide microarrays that identify the PVDFTVAI motif (SEQ ID NO:36), supporting the specificity of antibody recognition.
Claims Coverage
The provided material includes one independent claim. The claim focuses on producing a protective antibody against Acinetobacter baumannii using a specific antigenic polypeptide and isolating an antibody that binds a defined motif and induces an effector function; no additional independent inventive features are provided in the partial claims set.
Producing a protective antibody by mammalian introduction of SEQ ID NO: 8 with adjuvant
A method comprising introducing a polypeptide comprising the sequence of SEQ ID NO: 8 into a mammal along with an adjuvant, and isolating the protective antibody.
Motif-directed binding and effector function against Acinetobacter baumannii
The protective antibody binds the motif FEDFN (SEQ ID NO: 37) and induces an effector function towards Acinetobacter baumannii.
Overall, claim coverage in the provided set centers on antibody production in a mammal using a specified polypeptide (SEQ ID NO: 8) with adjuvant, followed by isolating a protective antibody that binds the motif FEDFN (SEQ ID NO: 37) and induces effector function against Acinetobacter baumannii.
Stated Advantages
Protective antibody induction against Acinetobacter baumannii that binds FEDFN (SEQ ID NO:37) and induces effector function.
Documented Applications
Vaccine composition use based on antigenic Acinetobacter baumannii polypeptide targets and motif-directed antibodies.
Diagnostic composition use based on antigenic Acinetobacter baumannii targets and antibody binding concepts.
Therapeutic use of antibodies/antigenic targets against Acinetobacter baumannii, including protective and effector-function-capable antibodies.
Interested in licensing this patent?